RASSF1A gene methylation and its clinical significance in leukemia patients

Abstract

Abstract: Objective　To research Ras association domain family 1A（RASSF1A） gene promoter region methylation in bone marrow of leukemia patients and its clinical significance. Methods　Methylation of RASSF1A gene promoter region was detected by methylation specific polymerase chain reaction（MS-PCR） in the bone marrow of 86 leukemia patients，and the difference of different kinds of leukemia was analyzed. A total of 60 non-leukemia subjects were enrolled as controls. Results　Twelve of 86（13.95%） leukemia patients had RASSF1A gene promoter region methylation. No methylation was found in bone marrow of the control group，and there was a statistical significance（P＜0.05）. RASSF1A gene methylation ratio in lymphoid leukemia（23.1%） was higher than that in myeloid leukemia（6.4%）（P＜0.05）. Conclusions　Leukemia patients have RASSF1A gene methylation. The ratio of RASSF1A gene methyaltion in lymphoid leukemia is obviously higher than that in myeloid leukemia. RASSF1A gene methyaltion may be a significant parameter for diagnosis and genotyping of patients with leukemia.

Key words: Ras association domain family 1A gene, Leukemia, Methylation, Biomarker

CHEN Weiqun;HUANG Chen;ZHAN Xiyan;LIU Shuiyi;YU Jie;ZHANG Hongmei;LU Zhongxin . RASSF1A gene methylation and its clinical significance in leukemia patients[J]. , 2012, 27(7): 554-556.

References

[1]Dunwell T，Hesson L，Rauch TA，et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers [J]. Mol Cancer，2010，9：44.
[2]Richter AM，Pfeifer GP，Dammann RH. The RASSF proteins in cancer；from epigenetic silencing to functional characterization [J]. Biochim Biophys Acta，2009，1796（2）：114-128.
[3]Kurkjian C，Kummar S，Murgo AJ. DNA Methylation：its role in cancer development and therapy[J]. Curr Probl Cancer，2008，32（5）：187-235.
[4]Wang J，Wang B，Chen X，et al. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma：a systematic review and meta-analysis [J]. Carcinogenesis，2011，32（3）：411-416.
[5]Hu L，Chen G，Yu H，et al. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma [J]. Hepatol Int，2010，4（1）：423-432.
[6]Wang T，Liu H，Chen Y，et al. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma [J]. J Exp Clin Cancer Res，2009，28：160.
[7]Kang S，Kim HS，Seo SS，et al. Inverse correlation between RASSF1A hypermethylation，KRAS and BRAF mutations in cervical adenocarcinoma [J]. Gynecol Oncol，2007，105（3）：662-666.
[8]Ma L，Guo Q，Ma Y，et al. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers [J]. Eur J Gynaecol Oncol，2009，30（4）：370-374.
[9]Martins AT，Monteiro P，Ramalho-Carvalho J，et al. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions [J]. Breast Cancer Res Treat，2011，129（1）：1-9.
[10]Harada K，Toyooka S，Maitra A，et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines[J]. Oncogene，2002，21（27）：4345-4349.
[11]Johan MF，Bowen DT，Frew ME，et al. Aberrant methylation of the negative regulators RASSFIA SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia[J]. Br J Haematol，2005，129（1）：60-65.
[12]Avramouli A，Tsochas S，Mandala E，et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia[J]. Leuk Res，2009，33（8）：1130-1132.

[1]	SUN Zepeng, WANG Hongbin, WANG Jiandong, SONG Dewei, XIAO Peng. Analysis and progress of peptide and protein biomarker methodology for myocardial injury [J]. Laboratory Medicine, 2023, 38(8): 784-789.
[2]	WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691.
[3]	ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598.
[4]	GAO Feng. Clinical application of novel tumor biomarkers：prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306.
[5]	LIU Junshan, GUO Mingfa, SUN Jia, SHI Lihuan, LIU Wei, DUAN Yongtao. Significance of minimal residual disease dynamic monitoring in the prognosis of acute B-lymphoblastic leukemia children with positive and negative ETV6/RUNX1 fusion genes [J]. Laboratory Medicine, 2023, 38(3): 209-214.
[6]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[7]	ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210.
[8]	BAI Wei, WANG Bin, GUO Jiarui, ZHU Guangpu, ZHU Liyan. Expression of PBX1 in osteosarcoma tissues and its influence on prognosis [J]. Laboratory Medicine, 2023, 38(10): 926-929.
[9]	DING Jing, LIU Weiling, XIA Xinxin, LIN Lihui. Analysis of chronic mast cell leukemia secondary to hematopoietic stem cell transplantation in myelodysplastic syndrome [J]. Laboratory Medicine, 2023, 38(10): 971-976.
[10]	LU Qiyuan, LU Jianhua. Biomarker research progress for the diagnosis of periprosthetic joint infection [J]. Laboratory Medicine, 2023, 38(10): 997-1002.
[11]	CHEN Xuewei, LI Yirong. Candidate biomarkers in metabolic syndrome based on GEO database [J]. Laboratory Medicine, 2023, 38(1): 32-38.
[12]	WANG Ruijuan, LI Chao, DUAN Lijuan, SHANG Miao, YANG Ruyu. Expression and clinical significance of lncRNA RBM5-AS1 in acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(1): 39-45.
[13]	WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99.
[14]	WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881.
[15]	YU Lisha, ZHANG Yingying. Screening and bioinformatics analysis of differential genes in children with acute lymphoblastic leukemia based on GEO database [J]. Laboratory Medicine, 2022, 37(8): 745-750.